Peter J. Weiden, MD, PhD

Randomized, Double-Blind, Active-Controlled Study of Starting Aripiprazole Lauroxil With 1-Day Initiation in Acutely Ill Patients With Schizophrenia

Objective: Evaluate efficacy and safety of a 2-month dose of aripiprazole lauroxil (AL) with a 1-day initiation regimen during hospitalization for an acute exacerbation of schizophrenia. ...

Sergey Yagoda , PhD, MD;

David Walling , PhD, CNS, MD;

Jelena Kunovac , MD;

Amy Claxton , PhD;

Yangchun Du , PhD;

Peter J. Weiden , MD, PhD;

11/22/2019

Patient Preferences Concerning the Efficacy and Side Effect Profile of Schizophrenia Medication: A Survey of Patients Living With Schizophrenia

This poster was presented at the 31st annual Psych Congress, held Oct. 25-28, 2018, in Orlando, Florida. Background: A survey was carried out to investigate the relative importance of an...

Eric Achtyes , MD;

Anna Skabeev , MD;

Ying Jiang , PhD;

Peter J. Weiden , MD, PhD;

Patricia Marcy , BSN;

Nikki Levy , BS ;

Adam Simmons , MPH;

03/01/2019

An Ongoing Randomized Double-blind Active-controlled Study of Starting Aripiprazole Lauroxil with a 1-Day Initiation Regimen in Acutely Ill Subjects with Schizophrenia: Rationale, Study Design, and Patient Population at Baseline

Recent FDA approvals provide physicians the opportunity to initiate long-acting injectable (LAI) antipsychotics in acute settings, but there is limited research comparing the efficacy an...

Amy Claxton , PhD;

Yangchun Du , PhD;

Peter J. Weiden , MD, PhD;

03/01/2019

A New Method for Initiating Treatment With the Long-acting Antipsychotic Aripiprazole Lauroxil

BACKGROUND: Significant delay can occur between the first dose of a long-acting injectable (LAI) antipsychotic and achievement of efficacious plasma concentrations, which is usually addre...

Lisa L. von Moltke , MD, FCPP;

Bhaskar Rege , PhD, BPharm;

Peter J. Weiden , MD, PhD;

Jonathan Meyer , MD;

Rakesh Jain , MD, MPH, RD;

Angela Wehr , PhD;

03/01/2019

Outcomes From OASIS: Observational Study of Long-Acting Injectables in Schizophrenia

OASIS was an observational study that evaluated real-world outcomes of atypical long-acting injectable (aLAI) antipsychotics in patients with schizophrenia. Overall, CGI-S scores at basel...

Peter J. Weiden , MD, PhD;

10/26/2023